ClinicalTrials.gg
Status unknownNCT01500395Updated Jan 1, 2016

Hybrid Operation in Thoracic Aortic Dissection

An observational study in Aorta Dissection and Aorta Aneurysm, sponsored by Xijing Hospital. Status unknown at 1 site in China. Open to participants aged 12 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-01-01.

Sponsored by Xijing Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2015), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
12 Years to 90 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the short to mid term efficacy and safety of different hybrid operations who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Read the detailed description

Aneurysms and dissection involving the ascending aorta and aortic arch have historically been treated with open surgical techniques, requiring cardiopulmonary bypass and deep hypothermic circulatory arrest (DHCA). Despite increasing experience and refinement of these procedures, there remains a substantial rate of morality and morbidity. The goal of hybrid operations is to re-construct the ascending aorta and aortic arch to cover the primary entry tear of the dissection and to remodel the aorta. Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. The purpose of this study is to investigate the short to mid term efficacy and safety of different hybrid operations who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study designs to enroll 50 patients to be monitored for 24 months.

02

Conditions studied

  • Aorta Dissection
  • Aorta Aneurysm

Keywords

  • Aortic Diseases
  • Vascular Diseases
  • Cardiovascular Diseases
  • Treatment Outcome
  • Aorta Dissection
  • Aorta Aneurysm
  • Aorta pseudoaneurysm
  • Endovascular aortic repair
  • Hybrid operation
  • Debranching
03

In context

Aortic Dissection

205 studies on the registry are indexed under Aortic Dissection; 73 are open to participants now.

This study's planned enrollment of 50 is below the median of 230 across 115 observational studies indexed under Aortic Dissection.

Browse Aortic Dissection studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 474 studies on the registry; 159 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Thoracic Aortic Dissection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ascending aortic/arch aneurysm
  • Ascending aortic/arch pseudo-aneurysm
  • Stanford Type A dissection
  • Retrograde Stanford Type B dissection
  • Unclassified dissection with primary tear located in the aortic arch
  • Able to tolerate endotracheal intubation and general anesthesia
  • Subject's anatomy must meet the anatomical criteria to receive that implanted device
  • The subject or legal guardian understands the nature of the study and agrees to its provisions on a written form
  • Availability for the appropriate follow-up visits during the follow-up period
  • Capability to follow all study requirements

Exclusion criteria

Exclusion Criteria:

  • = V
  • Severe renal insufficiency defined as SVS risk renal status = 3
  • Severe respiratory insufficiency defined as SVS risk pulmonary status = 3
  • Presence of connective tissue disease
  • Active infection or active vasculitides
  • Pregnant woman or positive pregnancy test
  • Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment
  • Subject has had a cerebral vascular accident (CVA) within 2 months.
  • History of drug abuse
  • Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
  • Subject has a known allergy or intolerance to the device components.
  • Subject has a known or to anticoagulants or contrast media, which is not amenable to pre-treatment.
  • Subject has a co-morbidity causing expected survival to be less than 1 year.
  • Enrolment in another clinical study
  • Unwillingness to cooperate with study procedures or follow-up visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Stent Graft and open surgery

    Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.

    Procedure: Hybrid operation

Interventions

  • ProcedureHybrid operation

    Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft(Medtronic Medtronic, Inc., US) Microport Stent Graft(Microport Co.,LTD.,Shanghai, China) Ankura Stent Graft(Lifetech Scientific Co.,LTD.,Shenzhen, China).

    Also known as: Medtronic Stent Graft, Microport Stent Graft, Ankura Stent Graft

06

What researchers measure

Primary outcomes

  1. Cumulative MACE

    Cumulative MACE (including death, rupture, paraplegia, aneurysm formation et al)

    Time frame: 12 months

Secondary outcomes

  1. Endoleak

    Endoleak of all types from the stent graft

    Time frame: 12 months

  2. Stent-graft migration/kinking

    Stent-graft migration, stenosis, kinking and other conditions requiring re-intervention

    Time frame: 12 months

  3. Cumulative cerebrovascular events

    Cumulative cerebrovascular events as bleeding, thrombosis, paraplegia, transient unconsciousness, et al.

    Time frame: 12 months

  4. Liver/Kidney dysfunction

    Liver dysfunction including jaundice,transaminase elevation 1.5 times more than normal, et al. Kidney dysfunction including oliguria, anuria, Creatinine/BUN elevation 1.5 times more than normal, et al.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
    Xi'an, Shaanxi 710032, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01500395
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Dec 28, 2011
Start date
Nov 2011
Primary completion
Dec 2015 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jan 1, 2016

Study contacts

Jian Yang, MD,PhD
Contact
yangjian1212@hotmail.com
86-13892828016
Dinghua Yi, M.D., Ph.D
principal investigator · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Jian Yang, M.D., Ph.D.
study director · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Weixun Duan, M.D., Ph.D.
study director · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Shiqiang Yu, M.D.
study director · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Jincheng Liu, M.D.
study director · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
Wensheng Chen, M.D.
study director · Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion